Inflarx (IFRX) doses first COVID-19 patient with IFX-1
Inflarx NV (IFRX) currently trades at $5.92 and has grown by 54.97% today. InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands. They received initial positive human data from its licensee, Beijing Defengrei Biotechnology Co. Ltd. (BDB), suggesting a potential role of C5a in COVID-19.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating because Inflarx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. The high forecast for Inflarx NV is $4.00 and the low is $3.00. Notably, the company’s market cap is $155.27 million with a 52 week high of $53.10 and a 52 week low of $2.17.